Microviable Therapeutics is a biotechnology company focused on developing innovative biological drugs and personalized therapies based on the microbiota. With a mission to improve human health, they are developing new biologics and personalized therapies using commensal bacteria to treat infectious diseases. Their leading candidate, MVT-201, is an orally administered capsule that represents the complete microbiota and will enter clinical trials in Q4 2023.

Their PharmaBiota® platform has allowed them to create a diverse collection of bacterial cultures, forming the foundation for the development of a new generation of bioterapeutics. With four other programs in preclinical stages, Microviable Therapeutics aims to harness the power of the microbiota to enhance the quality of life for their patients. They also collaborate with Inmunomet Intolerancias y Disbiosis to develop personalized therapies based on the microbiota.

In addition to their internal programs, they offer tailored projects for the pharmaceutical, food, and biotechnology industries, as well as microbiota analysis and microbiome storage services. Microviable Therapeutics is committed to advancing precision medicine through the microbiota